Evidence map›Paper›PMID 24644377›Full record

ArticleIranian journal of medical sciences2014

Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study.

Shervin Ziabakhsh-Tabary, Rozita Jalalian, Farzad Mokhtari-Esbuie, Mohammad Reza Habibi

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02984111 nacompletednot on this mapstarted 2016, after this paper: background citation

Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2016 to 2017Enrolled97ConditionsMyocardial Ischemic Reperfusion InjuryArmsnormal saline, erythropoietin
NCT06542393 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Patient Blood Manegement (PBM) as Perioperative Strategy to Anemic Patients Who Will be Submitted to Coronary Artery Bypass Graft (CABG).

TypeinterventionalSponsorFederal University of São PauloRan2024 to 2026Enrolled120ConditionsAnemia, Coronary Disease, Coronary Artery Disease, Coronary StenosisArmsErythropoietin, blood transfusion
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shervin Ziabakhsh-TabaryDepartment of Cardiac Surgery, Fatemeh Zahra Hospital, Mazandaran University of Medical Sciences, Sari, Iran;
Rozita JalalianDepartment of Cardiovascular, Fatemeh Zahra Hospital, Mazandaran University of Medical Sciences, Sari, Iran;
Farzad Mokhtari-EsbuieGeneral Physician, Fatemeh Zahra Hospital, Mazandaran University of Medical Science, Sari, Iran;
Mohammad Reza HabibiDepartment of Anesthesiology, Fatemeh Zahra Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Mazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythropoietin (EPO) is known as a regulating hormone for the production of red blood cells, called erythropoiesis. Some studies have shown that EPO exerts some non-hematopoietic protective effects on ischemia-reperfusion injuries in myocytes. Using echocardiography, we evaluated the effect of EPO infusion on reducing ischemia-reperfusion injuries and improvement of the cardiac function shortly after coronary artery bypass graft surgery (CABG).

methodsForty-three patients were recruited in this study and randomly divided into two groups: the EPO group, receiving standard medication and CABG surgery plus EPO (700 IU/kg), and the control group, receiving standard medication and CABG surgery plus normal saline (10 cc) as placebo. The cardiac function was assessed through echocardiography before as well as at 4 and 30 days after CABG.

resultsEchocardiography indicated that the ejection fraction had no differences between the EPO and control groups at 4 days (47.05±6.29 vs. 45.90±4.97; P=0.334) and 30 days after surgery (47.27±28 vs. 46.62±5.7; P=0.69). There were no differences between the EPO and control groups in the wall motion score index at 4 (P=0.83) and 30 days after surgery (P=0.902). In the EPO group, there was a reduction in left ventricular end-systolic and end-diastolic diameters (LVESD and LVEDD, respectively), as compared to the control group.

conclusionOur results indicated that perioperative exogenous EPO infusion could not improve the ventricular function and wall motion index in the immediate post-CABG weeks. Nevertheless, a reduction in LVEDD and LVESD at 4 days and 30 days after CABG in the EPO group, by comparison with the control group, suggested that EPO correlated with a reduction in the remodeling of myocytes and reperfusion injuries early after CABG. TRIAL REGISTRATION NUMBER: 138809102799N1.

Indexed as

Coronary artery bypass graftErythropoietinIschemiaReperfusion injury

Identifiers

PMID24644377
PMCPMC3957019
OpenAlexW2264219967

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.